Global (United States, European Union and China) Electrocompetent Cells

Electrocompetent Cells Comprehensive Study by Type (Cloned Competent Cells, Agrobacterium tumefaciens Competent Cells, Expression Competent Cells), Application (Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable Dna Cloning, High-Throughput Cloning, Protein Expression, Mutagenesis, Single-Stranded Dna Production, Bacmid creation, Cre-lox recombination (PIR1/PIR2)), Phases (Lag Phase, Log Phase, Stationary Phase, Death Phase), End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs)) Players and Region - Global Market Outlook to 2028

Electrocompetent Cells Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Electrocompetent cells work using the electroporation process. Electrical pulses created pores that allow genetic material to permeate the bacterial membrane. Invitrogen offers a variety of electrocompetent E. coli cells to reliably clone DNA with high efficiency. Cells that are undergoing very rapid growth are made competent more easily than cells in other stages. The ongoing developments in molecular cloning research are driving the demand for electrocompetent cells. Various Pharmaceutical and biotechnological companies have ongoing research for such cells and further uses of such products.This growth is primarily driven by Advancements in Molecular Cloning Research Due to the Emergence of New Technologies .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Biotechnology sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (United States), Agilent Technologies (United States), Takara Bio (Japan), Promega Corporation (United States), Beijing TransGen Biotech Co., Ltd. (China), GeneScript Corporation (United States), Yeastern Biotech Co., Ltd. (Taiwan), New England Biolabs (United States) and QIAGEN N.V. (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In February 2018, LGC acquired Lucigen, a developer, manufacturer, and supplier of molecular biology enzymes, reagents, and kits. This acquisition increases companies' exposure to the NGS and gene editing markets.
In May 2020, Takara Bio USA, Inc. announced that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan.Despite the presence of competition and brand effect problems, due to the awareness of end-users and their demand for high-end products, investors are still optimistic about this area. There will be more new investors entering into this industry in the future. The manufacturers who want to occupy the market must depend on market mechanism reform, manufacturing equipment innovation, core technology improvement, and brand establishment.

Influencing Trend:
Increasing Research in DNA technologies

Market Growth Drivers:
Advancements in Molecular Cloning Research Due to the Emergence of New Technologies and Growing Commercial Demand for Molecular Cloned Products and Recombinant Proteins

Challenges:
Lack of Skilled Professionals

Restraints:
High Cost of Electrocompetent Cell Kits

Opportunities:
Advancements in Molecular Cloning Research and Emerging Applications of Electrocompetent Cells

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Electrocompetent Cells Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Electrocompetent Cells Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Electrocompetent Cells players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Electrocompetent Cells Study Sheds Light on
— The Electrocompetent Cells Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Electrocompetent Cells industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Electrocompetent Cells industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Cloned Competent Cells
  • Agrobacterium tumefaciens Competent Cells
  • Expression Competent Cells
By Application
  • Subcloning & Routine Cloning
  • Phage Display Library Construction
  • Toxic/Unstable Dna Cloning
  • High-Throughput Cloning
  • Protein Expression
  • Mutagenesis
  • Single-Stranded Dna Production
  • Bacmid creation
  • Cre-lox recombination (PIR1/PIR2)
By Phases
  • Lag Phase
  • Log Phase
  • Stationary Phase
  • Death Phase

By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations (CROs)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Advancements in Molecular Cloning Research Due to the Emergence of New Technologies
      • 3.2.2. Growing Commercial Demand for Molecular Cloned Products and Recombinant Proteins
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals
    • 3.4. Market Trends
      • 3.4.1. Increasing Research in DNA technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Electrocompetent Cells, by Type, Application, Phases, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Electrocompetent Cells (Value)
      • 5.2.1. Global Electrocompetent Cells by: Type (Value)
        • 5.2.1.1. Cloned Competent Cells
        • 5.2.1.2. Agrobacterium tumefaciens Competent Cells
        • 5.2.1.3. Expression Competent Cells
      • 5.2.2. Global Electrocompetent Cells by: Application (Value)
        • 5.2.2.1. Subcloning & Routine Cloning
        • 5.2.2.2. Phage Display Library Construction
        • 5.2.2.3. Toxic/Unstable Dna Cloning
        • 5.2.2.4. High-Throughput Cloning
        • 5.2.2.5. Protein Expression
        • 5.2.2.6. Mutagenesis
        • 5.2.2.7. Single-Stranded Dna Production
        • 5.2.2.8. Bacmid creation
        • 5.2.2.9. Cre-lox recombination (PIR1/PIR2)
      • 5.2.3. Global Electrocompetent Cells by: Phases (Value)
        • 5.2.3.1. Lag Phase
        • 5.2.3.2. Log Phase
        • 5.2.3.3. Stationary Phase
        • 5.2.3.4. Death Phase
      • 5.2.4. Global Electrocompetent Cells by: End User (Value)
        • 5.2.4.1. Pharmaceutical and Biotechnology Companies
        • 5.2.4.2. Academic Research Institutes
        • 5.2.4.3. Contract Research Organizations (CROs)
      • 5.2.5. Global Electrocompetent Cells Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Electrocompetent Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Agilent Technologies (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takara Bio (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Promega Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Beijing TransGen Biotech Co., Ltd. (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GeneScript Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Yeastern Biotech Co., Ltd. (Taiwan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. New England Biolabs (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. QIAGEN N.V. (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Electrocompetent Cells Sale, by Type, Application, Phases, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Electrocompetent Cells (Value)
      • 7.2.1. Global Electrocompetent Cells by: Type (Value)
        • 7.2.1.1. Cloned Competent Cells
        • 7.2.1.2. Agrobacterium tumefaciens Competent Cells
        • 7.2.1.3. Expression Competent Cells
      • 7.2.2. Global Electrocompetent Cells by: Application (Value)
        • 7.2.2.1. Subcloning & Routine Cloning
        • 7.2.2.2. Phage Display Library Construction
        • 7.2.2.3. Toxic/Unstable Dna Cloning
        • 7.2.2.4. High-Throughput Cloning
        • 7.2.2.5. Protein Expression
        • 7.2.2.6. Mutagenesis
        • 7.2.2.7. Single-Stranded Dna Production
        • 7.2.2.8. Bacmid creation
        • 7.2.2.9. Cre-lox recombination (PIR1/PIR2)
      • 7.2.3. Global Electrocompetent Cells by: Phases (Value)
        • 7.2.3.1. Lag Phase
        • 7.2.3.2. Log Phase
        • 7.2.3.3. Stationary Phase
        • 7.2.3.4. Death Phase
      • 7.2.4. Global Electrocompetent Cells by: End User (Value)
        • 7.2.4.1. Pharmaceutical and Biotechnology Companies
        • 7.2.4.2. Academic Research Institutes
        • 7.2.4.3. Contract Research Organizations (CROs)
      • 7.2.5. Global Electrocompetent Cells Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Electrocompetent Cells: by Type(USD Million)
  • Table 2. Electrocompetent Cells Cloned Competent Cells , by Region USD Million (2017-2022)
  • Table 3. Electrocompetent Cells Agrobacterium tumefaciens Competent Cells , by Region USD Million (2017-2022)
  • Table 4. Electrocompetent Cells Expression Competent Cells , by Region USD Million (2017-2022)
  • Table 5. Electrocompetent Cells: by Application(USD Million)
  • Table 6. Electrocompetent Cells Subcloning & Routine Cloning , by Region USD Million (2017-2022)
  • Table 7. Electrocompetent Cells Phage Display Library Construction , by Region USD Million (2017-2022)
  • Table 8. Electrocompetent Cells Toxic/Unstable Dna Cloning , by Region USD Million (2017-2022)
  • Table 9. Electrocompetent Cells High-Throughput Cloning , by Region USD Million (2017-2022)
  • Table 10. Electrocompetent Cells Protein Expression , by Region USD Million (2017-2022)
  • Table 11. Electrocompetent Cells Mutagenesis , by Region USD Million (2017-2022)
  • Table 12. Electrocompetent Cells Single-Stranded Dna Production , by Region USD Million (2017-2022)
  • Table 13. Electrocompetent Cells Bacmid creation , by Region USD Million (2017-2022)
  • Table 14. Electrocompetent Cells Cre-lox recombination (PIR1/PIR2) , by Region USD Million (2017-2022)
  • Table 15. Electrocompetent Cells: by Phases(USD Million)
  • Table 16. Electrocompetent Cells Lag Phase , by Region USD Million (2017-2022)
  • Table 17. Electrocompetent Cells Log Phase , by Region USD Million (2017-2022)
  • Table 18. Electrocompetent Cells Stationary Phase , by Region USD Million (2017-2022)
  • Table 19. Electrocompetent Cells Death Phase , by Region USD Million (2017-2022)
  • Table 20. Electrocompetent Cells: by End User(USD Million)
  • Table 21. Electrocompetent Cells Pharmaceutical and Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 22. Electrocompetent Cells Academic Research Institutes , by Region USD Million (2017-2022)
  • Table 23. Electrocompetent Cells Contract Research Organizations (CROs) , by Region USD Million (2017-2022)
  • Table 24. South America Electrocompetent Cells, by Country USD Million (2017-2022)
  • Table 25. South America Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 26. South America Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 27. South America Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 28. South America Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 29. Brazil Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 30. Brazil Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 31. Brazil Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 32. Brazil Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 33. Argentina Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 34. Argentina Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 35. Argentina Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 36. Argentina Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 37. Rest of South America Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 38. Rest of South America Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 39. Rest of South America Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 40. Rest of South America Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 41. Asia Pacific Electrocompetent Cells, by Country USD Million (2017-2022)
  • Table 42. Asia Pacific Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 43. Asia Pacific Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 44. Asia Pacific Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 45. Asia Pacific Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 46. China Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 47. China Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 48. China Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 49. China Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 50. Japan Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 51. Japan Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 52. Japan Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 53. Japan Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 54. India Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 55. India Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 56. India Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 57. India Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 58. South Korea Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 59. South Korea Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 60. South Korea Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 61. South Korea Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 62. Taiwan Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 63. Taiwan Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 64. Taiwan Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 65. Taiwan Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 66. Australia Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 67. Australia Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 68. Australia Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 69. Australia Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 72. Rest of Asia-Pacific Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 73. Rest of Asia-Pacific Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 74. Europe Electrocompetent Cells, by Country USD Million (2017-2022)
  • Table 75. Europe Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 76. Europe Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 77. Europe Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 78. Europe Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 79. Germany Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 80. Germany Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 81. Germany Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 82. Germany Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 83. France Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 84. France Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 85. France Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 86. France Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 87. Italy Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 88. Italy Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 89. Italy Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 90. Italy Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 91. United Kingdom Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 92. United Kingdom Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 93. United Kingdom Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 94. United Kingdom Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 95. Netherlands Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 96. Netherlands Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 97. Netherlands Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 98. Netherlands Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 99. Rest of Europe Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 100. Rest of Europe Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 101. Rest of Europe Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 102. Rest of Europe Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 103. MEA Electrocompetent Cells, by Country USD Million (2017-2022)
  • Table 104. MEA Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 105. MEA Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 106. MEA Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 107. MEA Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 108. Middle East Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 109. Middle East Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 110. Middle East Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 111. Middle East Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 112. Africa Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 113. Africa Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 114. Africa Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 115. Africa Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 116. North America Electrocompetent Cells, by Country USD Million (2017-2022)
  • Table 117. North America Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 118. North America Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 119. North America Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 120. North America Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 121. United States Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 122. United States Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 123. United States Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 124. United States Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 125. Canada Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 126. Canada Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 127. Canada Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 128. Canada Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 129. Mexico Electrocompetent Cells, by Type USD Million (2017-2022)
  • Table 130. Mexico Electrocompetent Cells, by Application USD Million (2017-2022)
  • Table 131. Mexico Electrocompetent Cells, by Phases USD Million (2017-2022)
  • Table 132. Mexico Electrocompetent Cells, by End User USD Million (2017-2022)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Electrocompetent Cells: by Type(USD Million)
  • Table 144. Electrocompetent Cells Cloned Competent Cells , by Region USD Million (2023-2028)
  • Table 145. Electrocompetent Cells Agrobacterium tumefaciens Competent Cells , by Region USD Million (2023-2028)
  • Table 146. Electrocompetent Cells Expression Competent Cells , by Region USD Million (2023-2028)
  • Table 147. Electrocompetent Cells: by Application(USD Million)
  • Table 148. Electrocompetent Cells Subcloning & Routine Cloning , by Region USD Million (2023-2028)
  • Table 149. Electrocompetent Cells Phage Display Library Construction , by Region USD Million (2023-2028)
  • Table 150. Electrocompetent Cells Toxic/Unstable Dna Cloning , by Region USD Million (2023-2028)
  • Table 151. Electrocompetent Cells High-Throughput Cloning , by Region USD Million (2023-2028)
  • Table 152. Electrocompetent Cells Protein Expression , by Region USD Million (2023-2028)
  • Table 153. Electrocompetent Cells Mutagenesis , by Region USD Million (2023-2028)
  • Table 154. Electrocompetent Cells Single-Stranded Dna Production , by Region USD Million (2023-2028)
  • Table 155. Electrocompetent Cells Bacmid creation , by Region USD Million (2023-2028)
  • Table 156. Electrocompetent Cells Cre-lox recombination (PIR1/PIR2) , by Region USD Million (2023-2028)
  • Table 157. Electrocompetent Cells: by Phases(USD Million)
  • Table 158. Electrocompetent Cells Lag Phase , by Region USD Million (2023-2028)
  • Table 159. Electrocompetent Cells Log Phase , by Region USD Million (2023-2028)
  • Table 160. Electrocompetent Cells Stationary Phase , by Region USD Million (2023-2028)
  • Table 161. Electrocompetent Cells Death Phase , by Region USD Million (2023-2028)
  • Table 162. Electrocompetent Cells: by End User(USD Million)
  • Table 163. Electrocompetent Cells Pharmaceutical and Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 164. Electrocompetent Cells Academic Research Institutes , by Region USD Million (2023-2028)
  • Table 165. Electrocompetent Cells Contract Research Organizations (CROs) , by Region USD Million (2023-2028)
  • Table 166. South America Electrocompetent Cells, by Country USD Million (2023-2028)
  • Table 167. South America Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 168. South America Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 169. South America Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 170. South America Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 171. Brazil Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 172. Brazil Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 173. Brazil Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 174. Brazil Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 175. Argentina Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 176. Argentina Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 177. Argentina Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 178. Argentina Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 179. Rest of South America Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 180. Rest of South America Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 181. Rest of South America Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 182. Rest of South America Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 183. Asia Pacific Electrocompetent Cells, by Country USD Million (2023-2028)
  • Table 184. Asia Pacific Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 185. Asia Pacific Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 186. Asia Pacific Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 187. Asia Pacific Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 188. China Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 189. China Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 190. China Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 191. China Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 192. Japan Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 193. Japan Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 194. Japan Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 195. Japan Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 196. India Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 197. India Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 198. India Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 199. India Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 200. South Korea Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 201. South Korea Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 202. South Korea Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 203. South Korea Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 204. Taiwan Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 205. Taiwan Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 206. Taiwan Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 207. Taiwan Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 208. Australia Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 209. Australia Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 210. Australia Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 211. Australia Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 212. Rest of Asia-Pacific Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 213. Rest of Asia-Pacific Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 214. Rest of Asia-Pacific Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 215. Rest of Asia-Pacific Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 216. Europe Electrocompetent Cells, by Country USD Million (2023-2028)
  • Table 217. Europe Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 218. Europe Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 219. Europe Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 220. Europe Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 221. Germany Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 222. Germany Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 223. Germany Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 224. Germany Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 225. France Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 226. France Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 227. France Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 228. France Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 229. Italy Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 230. Italy Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 231. Italy Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 232. Italy Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 233. United Kingdom Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 234. United Kingdom Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 235. United Kingdom Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 236. United Kingdom Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 237. Netherlands Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 238. Netherlands Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 239. Netherlands Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 240. Netherlands Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 241. Rest of Europe Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 242. Rest of Europe Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 243. Rest of Europe Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 244. Rest of Europe Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 245. MEA Electrocompetent Cells, by Country USD Million (2023-2028)
  • Table 246. MEA Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 247. MEA Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 248. MEA Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 249. MEA Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 250. Middle East Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 251. Middle East Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 252. Middle East Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 253. Middle East Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 254. Africa Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 255. Africa Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 256. Africa Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 257. Africa Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 258. North America Electrocompetent Cells, by Country USD Million (2023-2028)
  • Table 259. North America Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 260. North America Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 261. North America Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 262. North America Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 263. United States Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 264. United States Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 265. United States Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 266. United States Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 267. Canada Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 268. Canada Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 269. Canada Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 270. Canada Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 271. Mexico Electrocompetent Cells, by Type USD Million (2023-2028)
  • Table 272. Mexico Electrocompetent Cells, by Application USD Million (2023-2028)
  • Table 273. Mexico Electrocompetent Cells, by Phases USD Million (2023-2028)
  • Table 274. Mexico Electrocompetent Cells, by End User USD Million (2023-2028)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Electrocompetent Cells: by Type USD Million (2017-2022)
  • Figure 5. Global Electrocompetent Cells: by Application USD Million (2017-2022)
  • Figure 6. Global Electrocompetent Cells: by Phases USD Million (2017-2022)
  • Figure 7. Global Electrocompetent Cells: by End User USD Million (2017-2022)
  • Figure 8. South America Electrocompetent Cells Share (%), by Country
  • Figure 9. Asia Pacific Electrocompetent Cells Share (%), by Country
  • Figure 10. Europe Electrocompetent Cells Share (%), by Country
  • Figure 11. MEA Electrocompetent Cells Share (%), by Country
  • Figure 12. North America Electrocompetent Cells Share (%), by Country
  • Figure 13. Global Electrocompetent Cells share by Players 2022 (%)
  • Figure 14. Global Electrocompetent Cells share by Players (Top 3) 2022(%)
  • Figure 15. Global Electrocompetent Cells share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 19. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2022
  • Figure 21. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 22. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 23. Takara Bio (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Takara Bio (Japan) Revenue: by Geography 2022
  • Figure 25. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Promega Corporation (United States) Revenue: by Geography 2022
  • Figure 27. Beijing TransGen Biotech Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 28. Beijing TransGen Biotech Co., Ltd. (China) Revenue: by Geography 2022
  • Figure 29. GeneScript Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. GeneScript Corporation (United States) Revenue: by Geography 2022
  • Figure 31. Yeastern Biotech Co., Ltd. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 32. Yeastern Biotech Co., Ltd. (Taiwan) Revenue: by Geography 2022
  • Figure 33. New England Biolabs (United States) Revenue, Net Income and Gross profit
  • Figure 34. New England Biolabs (United States) Revenue: by Geography 2022
  • Figure 35. QIAGEN N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 36. QIAGEN N.V. (Germany) Revenue: by Geography 2022
  • Figure 37. Global Electrocompetent Cells: by Type USD Million (2023-2028)
  • Figure 38. Global Electrocompetent Cells: by Application USD Million (2023-2028)
  • Figure 39. Global Electrocompetent Cells: by Phases USD Million (2023-2028)
  • Figure 40. Global Electrocompetent Cells: by End User USD Million (2023-2028)
  • Figure 41. South America Electrocompetent Cells Share (%), by Country
  • Figure 42. Asia Pacific Electrocompetent Cells Share (%), by Country
  • Figure 43. Europe Electrocompetent Cells Share (%), by Country
  • Figure 44. MEA Electrocompetent Cells Share (%), by Country
  • Figure 45. North America Electrocompetent Cells Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Thermo Fisher Scientific, Inc. (United States)
  • Agilent Technologies (United States)
  • Takara Bio (Japan)
  • Promega Corporation (United States)
  • Beijing TransGen Biotech Co., Ltd. (China)
  • GeneScript Corporation (United States)
  • Yeastern Biotech Co., Ltd. (Taiwan)
  • New England Biolabs (United States)
  • QIAGEN N.V. (Germany)
Additional players considered in the study are as follows:
OriGene Technologies (United States) , Lucigen (United States) , Zymo Research (United States) , Bio-Rad Laboratories (United States) , Bioline (United Kingdom) , Delphi Genetics (Belgium) , IBA GmBH (Germany)
Select User Access Type

Key Highlights of Report


Oct 2023 242 Pages 68 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Electrocompetent Cells Quantitative research analysis
Global (United States, European Union and China) Electrocompetent Cells Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Electrocompetent Cells Market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (United States), Agilent Technologies (United States), Takara Bio (Japan), Promega Corporation (United States), Beijing TransGen Biotech Co., Ltd. (China), GeneScript Corporation (United States), Yeastern Biotech Co., Ltd. (Taiwan), New England Biolabs (United States) and QIAGEN N.V. (Germany) etc.
Subcloning & Routine Cloning segment in Global market to hold robust market share owing to "Advancements in Molecular Cloning Research Due to the Emergence of New Technologies ".
AMA Research predicts that North America and Europe Players will contribute to the maximum growth of Global Electrocompetent Cells market throughout the forecasted period.

Know More About Global (United States, European Union and China) Electrocompetent Cells Report?

Have a Query? Click Here

Other Related Reports

Chemically Competent Cells Comprehensive Study by Type (Cloned Competent Cells, Electro-competent Cells, Agrobacterium tumefaciens Competent Cells, Expression Competent Cells), Application (Cloning, ...
$ 3650
Cell Separation Technologies Comprehensive Study by Type (Gradient Centrifugation, Surface Markers Separation (Fluorescence-activated cell sorting (FACS), Magnetic-Activated Cell Sorting (MACS), Filt...
$ 3750
Confocal Raman Microscopes Comprehensive Study by Type (Desktop, Portable), Application (Pharmaceutics, R&D in Academia, Industrial Sector, Others) Players and Region - Global Market Outlook to 2027
$ 3500
Cell Signaling Comprehensive Study by Type (Endocrine Signaling, Paracrine Signaling, Autocrine Signaling, Juxtacrine Signaling, Other Signaling Types), Application (Research Applications , Medical A...
$ 3500
Micro Bioreactors Comprehensive Study by Type (24 Parallel Bioreactors, 48 Parallel Bioreactors, Others), Application (Sewage Treatment, Biochemical Engineering, Food Industry, Others), End User (Pha...
$ 3450
Cell Sorter Comprehensive Study by Type (Cell Sorters, Cell Sorting Reagents & Consumables, Cell Sorting Services), Application (Research Application, Immunology & Cancer Research, Stem Cell Research...
$ 3750